SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.730
-0.090 (-2.36%)
Jul 13, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $13 | Buy | Initiates | $13 | +248.53% | Jun 24, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $14 → $16 | Buy | Reiterates | $14 → $16 | +328.95% | Jun 17, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $6 | Buy | Maintains | $6 | +60.86% | Jun 16, 2026 |
| Citi | Citi | Buy Reiterates $11 | Buy | Reiterates | $11 | +194.91% | Jun 16, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $14 | Buy | Reiterates | $14 | +275.34% | Jun 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 | Buy | Reiterates | $10 | +168.10% | Jun 15, 2026 |
| Jefferies | Jefferies | Buy Initiates $11 | Buy | Initiates | $11 | +194.91% | May 20, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $15 | Buy | Maintains | $15 | +302.14% | May 14, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.